Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2021 · 10-Q
Revenue$86.00K$86.00K−36.8% vs Q3 2020 Net Income-$6.91M-$6.91MN/M vs Q3 2020 EPS Diluted-$0.17-$0.17N/M vs Q3 2020 Operating Income-$6,998,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,563,000N/M Margins · derivedOperating margin-8137.2%−4929.1 pt vs Q3 2020
Net margin-8038.4%−4731.8 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end